

- and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. *Ann Rheum Dis*. 2017; 76: 1515-1521.
19. Dougados M, Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. *Arthritis Rheum*. 1991; 34: 1218-1227.
 20. Kellgren JH. Diagnostic criteria for population studies. *Bull Rheum Dis*. 1962; 13: 291-292.
 21. Maksymowych WP, Lambert RG, Østergaard M, et al. MRI lesions in the sacroiliac joints of patients with spondylarthritis: an update of definitions and validation by the ASAS MRI Working Group. *Ann Rheum Dis*. 2019; 78: 1550-1558.
 22. Bray TJP, Jones A, Bennett AN, et al. Recommendations for acquisition and interpretation of MRI of the spine and sacroiliac joints in the diagnosis of axial spondyloarthritis in the UK. *Rheumatology (Oxford)*. 2019; 58: 1831-1838.
 23. Marchesoni A, D'Angelo S, Anzidei M, et al. Radiologist-rheumatologist multidisciplinary approach in the management of axial spondyloarthritis: a Delphi consensus statement. *Clin Exp Rheumatol*. 2019; 37: 575-584.
 24. Wanders A, Heijde DV, Landewé R, et al. Non-steroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. *Arthritis Rheum*. 2005; 52: 1756-1765.
 25. Sieper J, Listing J, Poddubnyy E, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). *Ann Rheum Dis*. 2016; 75: 1438-1443.
 26. Khanna Sharma S, Kadiyala V, Naidu G, Dhir V. A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis. *Int J Rheum Dis*. 2018; 21: 308-314.
 27. Heijde DV, Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. *Ann Rheum Dis* 2017; 76: 1340-1347.
 28. Nuovo Documento Congiunto su norma biologici biosimilari contenuta nell'art. 1 comma 407 della Legge n. 232/2016 alla luce del Secondo Position Paper AIFA; 4 maggio 2018. Available from: <https://www.reumatologia.it/obj/files/Biosimilari/DocumentoIntersocietario-BIO18.pdf>
 29. Lie E, Lindstrom U, Zverkova-Sandstrom T, et al. Tumour necrosis factor inhibitor treatment
 30. Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. *Ophthalmology* 2013; 120: 777-787.
 31. Gao X, Wendling D, Botteman MF, et al. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. *J Med Econ*. 2012; 15: 1054-1063.
 32. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind, placebo-controlled trial. *Gut*. 2012; 61: 1693-1700.
 33. Targan SR, Feagan BG, Vermeire S, et al. A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn's disease. *Gastroenterology*. 2012; 143: e26.
 34. Parisi S, Bortoluzzi A, Sebastiani GD, et al. The Italian Society for Rheumatology clinical practice guidelines for rheumatoid arthritis. *Reumatismo*. 2019; 71(S1): 22-49.
 35. Mariette X, Forger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. *Ann Rheum Dis*. 2018; 77: 228-233.
 36. Clowse ME, Forger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. *Ann Rheum Dis*. 2017; 76: 1890-1896.
 37. Olivieri I, Salvarani C, Cantini F, et al. Recommendations for starting anti TNF-alpha in patients with ankylosing spondylitis. *Reumatismo*. 2003; 55: 220-223.
 38. D'Angelo S, Padula A, Nigro A, et al. Italian evidence-based recommendations for the management of ankylosing spondylitis: the 3E Initiative in Rheumatology. *Clin Exp Rheumatol*. 2008; 26: 1005-1011.
 39. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Rheumatol*. 2016; 68: 282-298.